Table 2.

Pathological and clinical outcomes of four groups

	All patients, n = 136 (%)	ypT0N0, n = 39 (%)	ypT + N0, = 49 (%)	ypT0N+, n = 11 (%)	ypT + N+,n = 37 (%)	P value
Lymph node harvest, mean ± SD	21.0 ± 9.9	21.9 ± 11.6	18.3 ± 7.2	20.5 ± 7.8	23.6 ± 10.9	0.087
Metastatic lymph node, mean ± SD	0.8 ± 1.8	0	0	1.6 ± 1.2	2.6 ± 2.5	< 0.001
ypT stage						< 0.001
T0	50 (36.8)	39 (100)	0	11 (100)	0
T1	12 (8.8)	0	8 (16.3)	0	4 (10.8)
T2	22 (16.2)	0	15 (30.6)	0	7 (18.9)
T3	38 (27.9)	0	19 (38.8)	0	19 (51.4)
T4	14 (10.3)	0	7 (14.3)	0	7 (18.9)
ypN stage						< 0.001
N0	88 (64.7)	39 (100)	49 (100)	0	0
N1	37 (27.2)	0	0	10 (90.9)	27 (73.0)
N2	7 (5.1)	0	0	1 (9.1)	6 (16.2)
N3	4 (2.9)	0	0	0	4 (10.8)
ypTNM stage						< 0.001
I	62 (45.6)	39 (100)	23 (46.9)	0	0
II	19 (14.0)	0	19 (38.8)	0	0
III	38 (27.9)	0	7 (14.3)	10 (90.9)	21 (56.8)
IV	17 (12.5)	0	0	1 (9.1)	16 (43.2)
Major pathological response	76 (55.9)	39 (100)	18 (36.7)	11 (100)	8 (21.6)	< 0.001
TRG grade, primary tumor						< 0.001
1 (no residual tumor cell)	50 (36.8)	39 (100)	0	11 (100)	0
2 (residual tumor ≤ 10%)	26 (19.1)	0	18 (36.7)	0	8 (21.6)
3 (residual tumor ≤ 50%)	13 (9.6)	0	7 (14.3)	0	6 (16.2)
4 (residual tumor < 100%)	15 (11.0)	0	5 (10.2)	0	10 (27.0)
5 (no tumor regression)	32 (23.5)	0	19 (38.8)	0	13 (35.1)
Follow-up, cases	126	38	43	10	35	-
median (range), months	30 (1–90)
Death at last follow-up	57 (44.9)	6 (15.8)	19 (43.2)	5 (50)	27 (77.1)	< 0.001
Recurrence at last follow-up	69 (54.8)	10 (26.3)	24 (55.8)	7 (70)	28 (80)	< 0.001
Recurrence location						< 0.001
locoregional	16 (12.7)	2 (5.3)	5 (11.6)	1 (10.0)	8 (22.9)
Distant metastasis	22 (17.5)	6 (15.8)	4 (9.3)	6 (60.0)	6 (17.1)
Local + distant	6 (4.8)	0	5 (11.6)	0	1 (2.9)
Death	21 (16.7)	2 (5.3)	6 (14.0)	0	13 (37.1)
No details	4 (3.2)	0	4 (9.3)	0	0